74 results
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
17 Apr 24
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
7:30am
in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
31 Jan 24
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
8:00am
on the Company’s operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
9 Nov 23
Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
4:21pm
or disruption in supply chain; the success and advancement of the clinical development programs for istaroxime and the Company’s other product candidates … an adverse impact on the Company’s operations, including through disruption in supply chain or access to potential international clinical trial sites
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
7 Aug 23
Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates
4:02pm
impact on the Company’s clinical trials, clinical trial timelines or disruption in supply chain; the success and advancement of the clinical … countries which could have an adverse impact on the Company’s operations, including through disruption in supply chain or access to potential
8-K
EX-99.1
x2i8tgquqen mtdvq6
15 May 23
Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates
4:24pm
424B4
9jpytme87rypmy 9kxrk
20 Apr 23
Prospectus supplement with pricing info
6:03pm
8-K
EX-99.1
styfafm djww1vyqr47
3 Apr 23
Windtree Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Key Business Updates
7:25am
8-K
EX-99.1
j69mbjudvs7myg
5 Dec 22
Other Events
7:48am
8-K
EX-99.1
l675gkwxutlkgle1 z2y
14 Nov 22
Windtree Therapeutics Reports Third Quarter 2022 Financial Results and Provides Key Business Updates
7:33am
8-K
EX-99.1
rygu1r6
23 Aug 22
Windtree Therapeutics Announces KL4 Surfactant and AEROSURF® Global License Agreement
8:30am
8-K
EX-99.1
tff 53be8
11 Aug 22
Windtree Therapeutics Reports Second Quarter 2022 Financial Results and Provides Key Business Updates
4:06pm
8-K
EX-99.1
rwzt3axp
23 May 22
The study met its primary endpoint of improved systolic blood pressure (SBP) profile at 6 hours
4:01pm
8-K
EX-99.1
867f 9darlc
5 May 22
Windtree Therapeutics Reports First Quarter 2022 Financial Results and Provides Key Business Updates
4:04pm
8-K
EX-99.1
76udq1ueschhro1
20 Apr 22
Windtree Announces Positive Topline Results from Its
7:07am
8-K
EX-99.1
lmh3ol
31 Mar 22
Windtree Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Key Business Updates
7:05am